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ABSTRACT Coxiella burnetii is an intracellular bacterial pathogen and a signiﬁcant
cause of culture-negative endocarditis in the United States. Upon infection, the nas-
cent Coxiella phagosome fuses with the host endocytic pathway to form a large
lysosome-like vacuole called the parasitophorous vacuole (PV). The PV membrane is
rich in sterols, and drugs perturbing host cell cholesterol homeostasis inhibit PV for-
mation and bacterial growth. Using cholesterol supplementation of a cholesterol-free
cell model system, we found smaller PVs and reduced Coxiella growth as cellular
cholesterol concentration increased. Further, we observed in cells with cholesterol a
signiﬁcant number of nonfusogenic PVs that contained degraded bacteria, a pheno-
type not observed in cholesterol-free cells. Cholesterol had no effect on axenic Cox-
iella cultures, indicating that only intracellular bacteria are sensitive to cholesterol.
Live-cell microscopy revealed that both plasma membrane-derived cholesterol and
the exogenous cholesterol carrier protein low-density lipoprotein (LDL) trafﬁc to the
PV. To test the possibility that increasing PV cholesterol levels affects bacterial sur-
vival, infected cells were treated with U18666A, a drug that traps cholesterol in lyso-
somes and PVs. U18666A treatment led to PVs containing degraded bacteria and a
signiﬁcant loss in bacterial viability. The PV pH was signiﬁcantly more acidic in cells
with cholesterol or cells treated with U18666A, and the vacuolar ATPase inhibitor
baﬁlomycin blocked cholesterol-induced PV acidiﬁcation and bacterial death. Addi-
tionally, treatment of infected HeLa cells with several FDA-approved cholesterol-
altering drugs led to a loss of bacterial viability, a phenotype also rescued by baﬁlo-
mycin. Collectively, these data suggest that increasing PV cholesterol further acidiﬁes
the PV, leading to Coxiella death.
IMPORTANCE The intracellular Gram-negative bacterium Coxiella burnetii is a signiﬁ-
cant cause of culture-negative infectious endocarditis, which can be fatal if un-
treated. The existing treatment strategy requires prolonged antibiotic treatment,
with a 10-year mortality rate of 19% in treated patients. Therefore, new clinical ther-
apies are needed and can be achieved by better understanding C. burnetii patho-
genesis. Upon infection of host cells, C. burnetii grows within a specialized replica-
tion niche, the parasitophorous vacuole (PV). Recent data have linked cholesterol to
intracellular C. burnetii growth and PV formation, leading us to further decipher the
role of cholesterol during C. burnetii-host interaction. We observed that increasing
PV cholesterol concentration leads to increased acidiﬁcation of the PV and bacterial
death. Further, treatment with FDA-approved drugs that alter host cholesterol ho-
meostasis also killed C. burnetii through PV acidiﬁcation. Our ﬁndings suggest that
targeting host cholesterol metabolism might prove clinically efﬁcacious in control-
ling C. burnetii infection.
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Cholesterol is known to play key roles in cardiovascular disorders, obesity, diabetes,and infectious diseases caused by numerous bacterial, viral, and protozoal patho-
gens. Intracellular pathogens in particular target cholesterol at various stages of
infection. For example, Mycobacterium bovis and Helicobacter pylori directly target
cholesterol as a “docking site” to stabilize interactions with the host cell membrane and
initiate internalization (1–3). Mycobacterium spp., Brucella suis, Listeria monocytogenes,
Leishmania donovani, and Plasmodium falciparum appear to target cholesterol-rich lipid
rafts during entry into both phagocytic and nonphagocytic cells (3–13). Once inside the
cell, cholesterol is often targeted during establishment of the intracellular niche and
bacterial growth. For example, Mycobacterium tuberculosis and Mycobacterium leprae
accumulate cholesterol in the early phagosome as a mechanism to inhibit phagosome-
lysosome fusion and promote pathogen survival (14–16). M. tuberculosis also utilizes a
cholesterol import system to hijack host cell cholesterol as a carbon and energy source
(17). Chlamydia trachomatis intercepts cholesterol trafﬁcking from the Golgi apparatus
and incorporates cholesterol into the Chlamydia-containing inclusion body as well as
the bacterial cell wall (18). Thus, modulation of cellular cholesterol by diverse microbial
pathogens appears to play an important role in promoting pathogen entry, survival,
and subsequent disease.
Recent reports have implicated cholesterol as an important factor during infection
by the intracellular bacterial pathogen Coxiella burnetii, a signiﬁcant cause of culture-
negative endocarditis in the United States (19–21). An obligate intracellular pathogen
during natural infection, C. burnetii forms a unique niche in a modiﬁed acidic phagoly-
sosome known as the parasitophorous vacuole (PV). After uptake by the host cell via
phagocytosis, the bacterium resides in a tight-ﬁtting nascent phagosome that matures
through the default endocytic pathway (22, 23). Approximately 24 to 48 h postinfec-
tion, the C. burnetii PV expands through fusion with early and late endosomes,
lysosomes, and autophagosomes (24). As a result, the mature PV membrane is a hybrid
of host vesicular membranes, and the vacuole displays various characteristics of a
phagolysosome, including lysosomal hydrolases (acid phosphatase, cathepsin D, and
5=-nucleotidase) and an acidic pH of ~4.5 to 5 (24). Establishment of a replication-
competent PV requires the C. burnetii Dot/Icm type 4B secretion system (T4BSS), which
manipulates host cell trafﬁcking and signaling pathways via the activity of effector
proteins secreted into the host cytoplasm (25).
Formation of the C. burnetii PV is a highly dynamic process involving vesicular
trafﬁcking and fusion events, with the PV membrane playing a central role. A distin-
guishing feature of the C. burnetii PV membrane, based on staining with the ﬂuorescent
sterol-binding compound ﬁlipin, is that it is rich in sterols (21). A role for cholesterol
during C. burnetii infection was suggested by gene expression analysis of infected host
cells, which found that genes involved in cholesterol efﬂux and storage are upregulated
during C. burnetii infection (26, 27). Further, a recent screen of a FDA-approved drug
library identiﬁed 57 drugs that perturb host cell cholesterol homeostasis also block
C. burnetii growth in THP-1 human macrophage-like cells (19). Intriguingly, these drugs
had a more pronounced effect on C. burnetii than on Legionella pneumophila, Rickettsia
conorii, or Brucella abortus, suggesting that C. burnetii may be uniquely sensitive to
altered host cell cholesterol homeostasis. Additionally, when cholesterol transport from
endosomes and presumably the C. burnetii PV was blocked through knockdown of the
cholesterol transporter NPC-1, C. burnetii growth was signiﬁcantly attenuated (19).
Together, these studies suggest that cholesterol is an important player affecting the
C. burnetii-host cell interaction.
In order to further understand the role of cholesterol during C. burnetii infection, we
developed a novel cholesterol-free host cell tissue culture system using cells lacking
DHCR24, the ﬁnal enzyme in cholesterol biosynthesis (20). When adapted to serum-free
media, DHCR24/ mouse embryonic ﬁbroblasts lack both endogenous and exoge-
nous cholesterol sources, and instead, they accumulate desmosterol in cellular mem-
branes. Cholesterol-free cells are an attractive model for deciphering the role of
cholesterol in cellular processes, enabling cholesterol manipulation by the addition of
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exogenous cholesterol to the media. Our prior studies with this model system revealed
that C. burnetii uptake into ﬁbroblast cells was dependent on cholesterol-rich lipid rafts
and the integrin v3 (20). Strikingly, C. burnetii PV formation and intracellular replica-
tion did not require cholesterol. Further, the PV acquired the typical PV markers Rab7,
ﬂotillin-2, syntaxin 7, syntaxin 8, and Vamp7 and contained active cathepsin, indicating
that the majority of PV maturation events occurred in the absence of cholesterol.
However, the lack of the late endosomal marker CD63 in the PV lumen in cholesterol-
free cells suggests that cholesterol regulates one or more intracellular trafﬁcking
pathways to the PV (20).
While studies thus far indicate that cholesterol plays a key role during C. burnetii
infection, how cholesterol affects the formation and maintenance of the PV, as well as
C. burnetii growth, is not yet known. Here, we utilized cholesterol-free cells to further
decipher the role of cholesterol in C. burnetii-host cell interactions. Our studies surpris-
ingly revealed that increasing cholesterol in the C. burnetii PV inhibits fusion between
the PV and endosomes, acidiﬁes the PV, and results in C. burnetii degradation. Our data
demonstrating a cholesterol-mediated negative effect on an intracellular bacterial
pathogen is novel and may have broader implications in the treatment of C. burnetii
infection.
RESULTS
PV size and C. burnetii growth are sensitive to cholesterol. DHCR24/ mouse
embryonic ﬁbroblast cells (MEFs) lack the ﬁnal enzyme in cholesterol biosynthesis.
When adapted to serum-free media, these cells are cholesterol free and accumulate
desmosterol in place of cholesterol (20). Cellular cholesterol levels can be controlled by
adding cholesterol to the culture medium, which is then preferentially incorporated
into cellular membranes over desmosterol (20). Using this model system, we can
observe the effect of cellular cholesterol on C. burnetii-host interactions over a range of
cholesterol concentrations and longer infection periods than those used in traditional
methods of manipulating cellular cholesterol.
We previously found that while C. burnetii entry was reduced, bacterial replication
did not appear to be signiﬁcantly affected in the absence of cholesterol (20). To
determine whether host cholesterol levels inﬂuence formation of the C. burnetii PV, we
infected DHCR24/ MEFs grown under different cholesterol concentrations and as-
sessed PV size over 6 days of infection using immunoﬂuorescence microscopy. Infected
cells were ﬁxed and stained using antibodies against C. burnetii and LAMP-1 (lysosome-
associated membrane glycoprotein 1), a lysosomal protein found on the PV membrane.
Surprisingly, at the beginning of PV expansion at 2 days postinfection, the average PV
size in cholesterol-free MEFs was at least twice as large as PVs in MEFs with cholesterol
(Fig. 1A). While PVs in cholesterol-free MEFs continued to expand approximately 8-fold
over the next 4 days, PVs in MEFs with cholesterol remained signiﬁcantly smaller
regardless of the cholesterol concentration (Fig. 1B and C). Given the dramatic effect of
cholesterol on PV size, we used quantitative PCR to measure C. burnetii growth. The fold
change in C. burnetii growth over 6 days decreased in a cholesterol-dependent manner,
with little growth seen at the highest cholesterol concentration (Fig. 1D). Together,
these data indicate that C. burnetii PV size and bacterial growth are negatively affected
by cholesterol.
Addition of cholesterol leads to C. burnetii lysis. Fixed-cell microscopy suggested
that poor bacterial growth in the presence of cholesterol was associated with deﬁcient
PV formation, similar to the observed phenotype for C. burnetii T4BSS mutants (28, 29).
To further examine this phenotype, we used live-cell imaging of MEFs with or without
cholesterol and infected with mCherry-expressing C. burnetii (mCherry-C. burnetii).
Surprisingly, we observed in MEFs with cholesterol a signiﬁcant number of PVs with free
mCherry ﬂuorescence in the PV lumen, a result of lysis or degradation of mCherry-
expressing C. burnetii (Fig. 2A, bottom panel). Because the bacteria have lysed, we have
designated these PVs “lytic.” By 2 days postinfection, approximately 20% of the PVs
were lytic in MEFs with cholesterol, regardless of the cholesterol concentration. Over
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FIG 1 PV size and C. burnetii growth are sensitive to cholesterol. (A to C) Measurement of PV sizes reveals
that PVs are signiﬁcantly smaller in MEFs with cholesterol compared to cholesterol-free MEFs. C. burnetii-
infected MEFs were incubated with the different cholesterol concentrations (0, 2.5, 5, or 10 g/ml) and
stained by immunoﬂuorescence for C. burnetii and the PV marker LAMP-1 at the indicated times (2, 4, and
6 days). PVs were measured using ImageJ. Each circle represents the value for 1 PV, with at least 15 PVs
per condition measured in each of three separate experiments. The means (black horizontal bars) were
compared by one-way ANOVA with Tukey’s posthoc test. Error bars represent the standard errors of the
means (SEM). The values that were signiﬁcantly different from the control values (no cholesterol) are
indicated by asterisks as follows: **, P  0.01; ***, P  0.001. (D) The fold change in bacterial growth
under different cholesterol conditions was determined by quantitative PCR for bacterial genomes. The
means plus standard deviations (SD) from three separate experiments done in duplicate are shown.
Values that are signiﬁcantly different from the control value (no cholesterol) determined by one-way
ANOVA with Dunnett’s posthoc test are indicated by asterisks as follows: *, P  0.05, ***, P  0.001. D6,
day 6; D0, day 0.
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the next 48 h, the percentage of lytic PVs in MEFs with cholesterol increased in a
dose-dependent fashion. Importantly, we never observed lytic PVs in cholesterol-free
MEFs (Fig. 2B). To determine whether live-cell microscopy data correlated with bacterial
viability, we measured viable bacteria using a ﬂuorescent infectious focus-forming unit
(FFU) assay (30). Bacteria were recovered from MEFs under different cholesterol con-
ditions, replated onto a monolayer of Vero cells, and incubated for 5 days. After
C. burnetii bacteria were stained, the numbers of ﬂuorescent foci were counted, with
one focus unit equivalent to one viable bacteria. Over a period of 6 days, the number
of viable C. burnetii in MEFs with cholesterol decreased 80 to 98% compared to the
number in cholesterol-free MEFs, depending on the cholesterol concentration (Fig. 2C).
These data suggest that, as opposed to a lack of bacterial growth, the addition of
cholesterol to cholesterol-free MEFs is bacteriolytic.
Cholesterol trafﬁcs to the C. burnetii PV.We next examined cholesterol trafﬁcking
in cholesterol-free MEFs to determine how the addition of exogenous cholesterol in our
FIG 2 Increasing cellular cholesterol leads to C. burnetii death. (A) Representative live-cell microscopy images of cholesterol-
free MEFs and MEFs with cholesterol and infected with mCherry-expressing C. burnetii (mCherry-C. burnetii). Note the presence
of mCherry ﬂuorescence in the PV lumen in MEFs with cholesterol. The white arrows point to the PVs. Bars  10 m. (B)
Quantitation of lytic PVs containing degraded bacteria under different cholesterol conditions. At different times postinfection,
PVs were observed by live-cell microscopy and scored as lytic if visible mCherry ﬂuorescence was present in the lumen. The
means  SEM from three experiments are shown. The means were compared by one-way ANOVA with Tukey’s posthoc test.
*, P  0.05 compared to the value with no cholesterol. (C) Cholesterol leads to fewer viable bacteria. C. burnetii-infected
cholesterol-free MEFs were grown with different cholesterol concentrations, and the number of viable bacteria was deter-
mined by ﬂuorescent infectious focus-forming unit (FFU) assay. Error bars show the SEM of the averages of three individual
experiments done in duplicate. Means were compared by one-way ANOVA with Tukey’s posthoc test. *, P  0.05 compared
to the value with no cholesterol.
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model system might lead to C. burnetii death. Exogenous cholesterol could be inter-
nalized into the cell through two mechanisms: insertion into the plasma membrane or
uptake of cholesterol-bound low-density lipoprotein (LDL). In the ﬁrst case, cholesterol
intercalates into the plasma membrane and is then distributed throughout the cell via
vesicular and nonvesicular pathways. This pathway also mimics trafﬁcking of endoge-
nous host cell cholesterol, which is synthesized in the endoplasmic reticulum (ER) and
then transported to the plasma membrane for cellular distribution. To examine whether
plasma membrane-derived cholesterol travels to the PV, we incubated C. burnetii-
infected DHCR24/ MEFs with ﬂuorescent BODIPY-cholesterol complexed to methyl-
-cyclodextrin, which leads to incorporation of the BODIPY-cholesterol into the plasma
membrane. After 24 h incubation at 37°C to allow for cellular trafﬁcking, live-cell
microscopy revealed ﬂuorescent cholesterol in vesicular structures and the C. burnetii
PV (see Fig. S1A in the supplemental material). We next examined trafﬁcking of
exogenous LDL, a major cholesterol-binding protein internalized by cells through
receptor-mediated endocytosis. Following incubation of infected DHCR24/ MEFs
with ﬂuorescent LDL for 4 h, ﬂuorescent LDL was found in the PV membrane and PV
lumen (Fig. S1B). Thus, at least two sources of cholesterol travel to the PV, suggesting
that cholesterol supplementation of cholesterol-free MEFs increases PV cholesterol.
U18666A-induced cholesterol accumulation in the PV is bacteriolytic. On the
basis of our cholesterol trafﬁcking data, we hypothesized that accumulation of choles-
terol in the PV leads to C. burnetii death. The cholesterol-altering drug U18666A blocks
cholesterol transport from endosomes and lysosomes and results in cholesterol accu-
mulation in the endolysosomal system (31). To determine whether U18666A also leads
to cholesterol accumulation in the PV, we treated infected HeLa cells with U18666A and
then stained with ﬁlipin to label cholesterol and antibodies against LAMP-1 and
C. burnetii. As previously shown, ﬁlipin staining of untreated infected cells shows the
presence of cholesterol or other sterols in the PV membrane (Fig. 3A, top). However,
after U18666A treatment, there is a signiﬁcant increase in ﬁlipin labeling in and around
the PV (Fig. 3A, bottom), suggesting an increase in PV cholesterol. By live-cell micros-
copy, we observed a signiﬁcant number of lytic PVs shortly after adding U18666A to
mCherry-C. burnetii-infected HeLa cells. When quantitated after a 6 h treatment of
either 1 M and 5 M U18666A, approximately 30% and 85% of PVs were lytic,
respectively (Fig. 3B). Furthermore, the presence of lytic PVs corresponded with a 30 to
60% loss of bacterial viability, depending on the U18666A concentration (Fig. 3C).
Cumulatively, these data suggest that U18666A-induced cholesterol accumulation in
the PV leads to C. burnetii death.
To address the possibility that cholesterol could be directly killing C. burnetii, we
measured growth of axenic C. burnetii cultures in the presence or absence of choles-
terol. Compared to the carrier protein bovine serum albumin (BSA), cholesterol had no
effect on C. burnetii growth (Fig. S2A). Further, the bacteriolytic effect of U18666A is not
due to a direct effect on C. burnetii, as the addition of U18666A to C. burnetii axenic
cultures did not affect viability (Fig. S2B). These data indicate that the toxic effect of
cholesterol and U18666A is speciﬁc to the C. burnetii intracellular niche.
C. burnetii growth is most sensitive to cholesterol during the early stages of PV
biogenesis. During the ﬁrst 24 to 48 h of infection, C. burnetii resides in a tight-ﬁtting
PV, as the nonreplicating small-cell variant (SCV) transitions into the replication-
competent large-cell variant (LCV). During this time, the C. burnetii T4SS also secretes
effector proteins into the host cell cytoplasm, with secretion detected as early as 8 h
postinfection in HeLa cells and 1 h postinfection in mouse bone marrow-derived
macrophages (32). PV expansion around 48 h postinfection coincides with the begin-
ning of log-phase growth; LCVs transition back to SCVs around 5 or 6 days postinfection
(33). To determine whether C. burnetii is sensitive to cholesterol at speciﬁc stages of
infection, we added cholesterol to MEFs at 24 h intervals postinfection and assessed the
effect on PV size and bacterial viability. When cholesterol was added at the time of
infection or 1 day postinfection, the ﬁnal PVs at 6 days postinfection were signiﬁcantly
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smaller than those in cholesterol-free MEFs (Fig. 4A). However, there was no signiﬁcant
effect on ﬁnal PV size when cholesterol was added at any time after 1 day postinfection,
regardless of the cholesterol concentration. Similarly, the fold change in recoverable
bacteria over 6 days was sensitive to cholesterol only during the ﬁrst 2 days of infection,
with an approximately 80% decrease in bacterial viability in MEFs with cholesterol
compared to cholesterol-free MEFs (Fig. 4B). While not statistically signiﬁcant, choles-
terol addition after day 4 trended toward slightly larger PVs, although there was no
effect on bacterial viability. Based on these data, C. burnetii is sensitive to cholesterol
only during the early stages of PV expansion and log growth.
FIG 3 Altered cellular cholesterol homeostasis is bactericidal. (A) Microscopy images showing that U18666A
treatment traps cholesterol in the C. burnetii PV in HeLa cells. mCherry-C. burnetii-infected HeLa cells were treated
with 5 M U18666A for 6 h, ﬁxed, and stained for sterols (ﬁlipin) and PV (LAMP-1). Compared to mock-treated cells,
there is an increase in ﬁlipin labeling in and around the PV following treatment with U18666A. The white arrows
point to the PVs. Filipin intensity is shown as a heat map, with yellow showing the highest ﬁlipin intensity and blue
showing the lowest ﬁlipin intensity. Bars  5 m. (B) Quantitation of lytic PVs in U18666A-treated cells after
treatment of mCherry-C. burnetii-infected HeLa cells with 1 or 5 M U18666A. PVs were scored for the presence
(lytic) or absence (nonlytic) of free mCherry in the PV lumen, resulting from the lysis of mCherry-expressing
bacteria. The means plus SEM (error bars) from three individual experiments are shown. The means were compared
to the value with no cholesterol by one-way ANOVA with Dunnett’s posthoc test, and statistically different values
are indicated by asterisks as follows: *, P  0.05; ****, P  0.0001. (C) C. burnetii viability decreases after 6 h
treatment with U18666A. The number of viable bacteria was determined by FFU assay and normalized to the values
for the vehicle control (0 M). The means plus SEM (error bars) from three individual experiments are shown.
Statistical signiﬁcance was determined by comparing values to the value with no cholesterol by one-way ANOVA
with Dunnett’s posthoc test and indicated as follows: **, P  0.01; ****, P  0.0001. The average values for three
independent experiments done in duplicate are shown.
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Lytic PVs are nonfusogenic. The C. burnetii PV is a highly dynamic vacuole,
promiscuously fusing with vesicles from the endocytic pathway (34). We previously
observed cholesterol-dependent fusion between late endosomes and the PV, based on
a lack of the late endosome marker CD63 in the PV lumen in cholesterol-free MEFs (20).
To further characterize the effect of cholesterol on endosomal trafﬁcking to the PV, we
developed a quantitative fusogenicity assay utilizing ﬂuorescent dextran. Dextran is
internalized by cells through non-receptor-mediated endocytosis and accumulates in
the PV lumen following fusion between endosomes and the PV (35). To measure
PV-endosome fusion, we quantitated dextran accumulation in the PV lumen in MEFs
with or without cholesterol. MEFs infected with mCherry-C. burnetii were pulsed for
10 min with ﬂuorescent dextran and then imaged for 40 min using live-cell confocal
microscopy (Fig. 5A and B). The accumulation of dextran in the PV lumen in individual
PVs was determined by measuring the fold change in ﬂuorescence intensity over
FIG 4 C. burnetii growth is sensitive to cholesterol during early stages of PV biogenesis. (A) Final PV size after
adding cholesterol at various times postinfection in MEFs. Cholesterol-free MEFs were infected with C. burnetii and
different cholesterol concentrations were added to the cells each day from day 0 to 5. At day 6, cells were ﬁxed
and stained for the PV marker LAMP-1 and C. burnetii, and PV size was measured using ImageJ. At least 20 PVs were
measured for each condition for three independent experiments. Each circle indicates the value for an individual
PV. The means (black bars)  SEM (error bars) from three individual experiments are shown. Statistical signiﬁcance
was determined by comparing values to the value with no cholesterol by one-way ANOVA with Dunnett’s posthoc
test and indicated as follows: **, P  0.01; ****, P  0.0001. (B) Recoverable bacteria at day 6 post infection after
cholesterol addition at various times postinfection in MEFs. C. burnetii-infected cholesterol-free MEFs were grown
with different cholesterol concentrations added at different times postinfection. Bacterial viability was measured at
day 6 by FFU assay. The results shown are representative of three separate experiments performed in duplicate. The
means plus SD (error bars) are shown. Statistical signiﬁcance was determined by comparing values to the value
with no cholesterol by two-way ANOVA with Tukey’s posthoc test and indicated as follows: *, P  0.05; **, P 
0.001; ***, P  0.001.
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40 min. An average of 4.2-fold increase in ﬂuorescent dextran was observed in PVs from
cholesterol-free MEFs (Fig. 5C). In cells with cholesterol, PVs that were not yet lytic were
less fusogenic, with an average of 2.5-fold increase in ﬂuorescent dextran. In contrast,
lytic PVs (deﬁned as having a twofold increase in PV lumen mCherry ﬂuorescence
compared to background) accumulated little to no ﬂuorescent dextran, indicating that
PVs containing degraded bacteria are no longer fusogenic with the endocytic pathway.
Cholesterol further acidiﬁes the C. burnetii PV. Experiments in cholesterol-rich
macrophages have shown that cholesterol affects the ability of lysosomes to maintain
an acidic pH (36), raising the possibility that cholesterol inﬂuences PV pH. Prior studies
using ratiometric pH measurements with ﬂuorescein found the C. burnetii PV pH to be
approximately 4.8 (37, 38). Further, C. burnetii metabolism is activated by acidic pH (39,
40), and blocking PV acidiﬁcation during phagosome maturation using the vacuolar
ATPase (vATPase) inhibitor baﬁlomycin A1 inhibits bacterial growth (35). Collectively,
these data demonstrate that PV pH is a critical component of C. burnetii pathogenesis.
To determine whether PV pH is affected by cholesterol, we measured PV pH under
different cholesterol conditions using a microscopy-based ratiometric ﬂuorescence
FIG 5 Lytic PVs are nonfusogenic. (A and B) Representative microscopy images showing increased dextran accumulation in the lumen of PVs from MEFs grown
in cholesterol-free media (chol) compared to cells grown in media with cholesterol (chol). The cells are outlined in white in panel A, while panel B shows
2.5 insets of the PV and surrounding cytoplasm from panel A. MEFs infected with mCherry-expressing C. burnetii were pulsed with ﬂuorescent dextran for
10 min, washed with media to remove noninternalized dextran, followed by imaging of PVs every 6.3 min for 38 min. C. burnetii bacteria are shown in red, and
dextran is shown in white. The maximum z-axis projections are shown. Bars  10 m. In the t0 C. burnetii column in panel B, the C. burnetii image was mapped
to an intensity lookup table to visualize the lytic phenotype, with blue depicting the lowest ﬂuorescent intensity and yellow showing the highest intensity. Note
the presence of red ﬂuorescence in the PV lumen of the lytic PV. PVs are indicated by white arrowheads. The images were processed identically, and the gamma
was increased to 1.5 to more easily visualize PV dextran. (C) The fold change in total PV lumen dextran ﬂuorescence intensity at the end of the time course
versus time zero (t0) for the volume at 38 min postwashing (38 m p.w.). Each circle indicates the value for an individual PV, and the means standard deviations
of the means for groups of PVs are shown. Statistical signiﬁcance was determined by an unpaired t test and indicated as follows: *, P  0.05.
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assay (41). The pH-sensitive ﬂuorophore Oregon Green 488 is a ﬂuorescein derivative
with a pKa of 4.7, making Oregon Green 488 more accurate in acidic environments
compared to ﬂuorescein (pKa of 6.4) (41). MEFs with and without cholesterol were
infected with mCherry-C. burnetii for 3 days and then incubated with pH-sensitive
Oregon Green 488 dextran and pH-insensitive Alexa Fluor 647 dextran for 4 h to allow
for dextran trafﬁcking to the PV. It is important to note that because this assay relies on
dextran trafﬁcking to the PV, only nonlytic PVs in MEFs with cholesterol can be
analyzed, as lytic PVs are nonfusogenic (Fig. 5). The ﬂuorescence intensities of Oregon
Green 488 and Alexa Fluor 647 were measured for each PV, and a ratio of Oregon Green
488 to Alexa Fluor 647 was compared to a standard curve to generate individual PV pH
measurements. In cholesterol-free MEFs, the average PV pH was 5.1 with a range of 3.95
to 7.26 (Fig. 6A and Fig. S3). Interestingly, PVs in MEFs with cholesterol were signiﬁ-
cantly more acidic, ranging between 2.33 and 6.02 and an average pH of 4.4.
Given that U18666A also leads to lytic PVs, we measured PV pH before and after the
addition of U18666A to infected HeLa cells. After incubation with Oregon Green 488
dextran and Alexa Fluor 647 dextran for 4 h, PVs were imaged prior to adding dimethyl
sulfoxide (DMSO) or U18666A and then imaged every 15 min for 2 h. Similar to
cholesterol-free MEFs, the average PV pH prior to drug addition was approximately 5.1
(Fig. 6B and Fig. S4). While DMSO-treated cells maintained this pH over 2 h, in cells
treated with U18666A, the PV further acidiﬁed to an average pH of 4.4 within 30 min.
FIG 6 Cholesterol accumulation in the PV increases PV acidity. PV pH was determined at 3 days postinfection using a
ratiometric ﬂuorescence assay of pH-sensitive Oregon Green dextran and pH-insensitive Alexa 647 dextran. (A) The pH in
PVs from MEFs with cholesterol (average pH 4.5) was signiﬁcantly more acidic than PVs from cholesterol-free MEFs (average
pH 5.2). At least 10 PVs were measured in three separate experiments. The means  SEM (error bars) from three individual
experiments are shown. ****, P  0.0001 as determined by two-tailed unpaired t test. (B) Average PV pH over 2 h in HeLa
cells treated with DMSO or 5 M U18666A. PVs were identiﬁed by microscopy and imaged prior to adding drug. While PV
pH in DMSO-treated cells remained stable over the time course, PVs in U18666A-treated cells further acidiﬁed in the ﬁrst
30 min. The average pH values at 30 min were 5.1 in DMSO-treated cells and 4.4 in U1666A-treated cells. Approximately
10 PVs were measured in each of two separate experiments, and individual traces are shown in Fig. S4 in the supplemental
material. The averages  SD (error bars) are shown. All time points were signiﬁcant (P  0.0001). (C) C. burnetii-infected
HeLa cells were treated with U18666A (1 M or 5 M) and/or the vATPase inhibitor baﬁlomycin A1 (100 nM) for 3 h.
Bacterial viability, as measured by the FFU assay, is rescued in the presence of baﬁlomycin. The means plus SEM (error bars)
from three individual experiments are shown. ****, P 0.0001 for the value for U18666A treatment alone compared to the
value for no treatment as determined by one-way ANOVA with Tukey’s posthoc test.
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While these data suggest that cholesterol accumulation leads to PV acidiﬁcation, we
next tested whether increased acidiﬁcation was responsible for C. burnetii degradation.
The proton pump vacuolar ATPase is responsible for PV acidiﬁcation and can be
blocked using baﬁlomycin A1 (35). Baﬁlomycin A1 recovered bacterial viability in the
presence of U18666A (Fig. 6C), indicating that increased acidiﬁcation of the PV leads to
C. burnetii death.
Cholesterol-altering FDA-approved drugs lead to C. burnetii lysis. A previous
study discovered that numerous drugs from a FDA-approved drug library altered
cholesterol homeostasis in HeLa cells and inhibited intracellular C. burnetii growth (19).
To determine whether these drugs worked through a mechanism similar to that of
U18666A, we tested a small subset of drugs for their ability to induce lytic PVs in HeLa
cells. These drugs were chosen based on their ability to (i) cause cholesterol accumu-
lation in endosomes, (ii) block intracellular C. burnetii growth, (iii) not affect C. burnetii
growth in axenic media, and (iv) have low toxicity to host cells (19) (Table S1). Six of the
eight drugs we tested led to lytic PVs after a 3 h treatment (Fig. S5A). In particular,
loperamide, clemastine, and amiodarone resulted in nearly all of the PVs containing
degraded bacteria, with few intact bacteria (Fig. S5B and data not shown). These
observations correlated with almost no bacteria recovered after 3 h, as measured by a
FFU assay (Fig. 7A). Furthermore, concurrent incubation with baﬁlomycin A1 at least
partially rescued killing by amiodarone, clemastine, haloperidol, and spiperone, as
measured by a decrease in the number of lytic PVs (Fig. S5A) and an increase in
bacterial viability (Fig. 7A). This suggests that similar to U18666A, these drugs increase
the acidity of the PV.
To determine whether these drugs led to altered cholesterol levels in the PV, we
observed cholesterol by staining with ﬁlipin. While all of the drugs tested appeared to
alter cholesterol distribution, several phenotypes were observed (summarized in Ta-
ble S1). Compared to DMSO-treated cells, amiodarone did not signiﬁcantly alter overall
ﬁllipin labeling intensity of endosomes. However, unlike ﬁlipin labeling being restricted
to the PV membrane of control cells, amiodarone treatment led to signiﬁcant ﬁlipin
labeling of the PV lumen (Fig. 7B, insets). In contrast, ﬁlipin primarily labeled the PV
membrane in clemastine-treated cells, but there was a signiﬁcant increase in endo-
somal ﬁlipin labeling intensity. Haloperidol-treated cells had a phenotype similar to that
of clemastine-treated cells, while the phenotype of loperamide-treated cells was more
similar to that of U18666A-treated cells (Fig. S5). Intriguingly, spiperone-treated cells
appeared to have ﬁlipin levels similar to those in control cells, with some of the PVs
showing labeling within the PV lumen (Fig. S5). Together with the baﬁlomycin data, this
suggests that there might be multiple mechanisms by which altering host cholesterol
leads to increased acidiﬁcation of the C. burnetii PV, and ultimately, death of the
bacteria. Interestingly, baﬁlomycin did not rescue the effects of loperamide, suggesting
that this drug may act through a different mechanism.
DISCUSSION
Cholesterol is a critical lipid constituent of cellular membranes, regulating mem-
brane dynamics, trafﬁcking, and signaling. Due to its involvement in important host cell
processes, an increasing number of pathogens, including Leishmania spp., Salmonella
enterica, Staphylococcus aureus, Mycobacterium spp., and Listeria monocytogenes, have
been reported to exploit host cell cholesterol (3–5, 11–13). To understand the role of
cholesterol during C. burnetii-host interaction, we utilized a cholesterol-free tissue
culture model system that lacks both endogenous cholesterol (from biosynthesis) and
exogenous cholesterol (from serum). In a previous study, we used this system to
establish that C. burnetii entry into ﬁbroblasts occurred through lipid raft-mediated
v3 signaling (20). In addition, with the exception of CD63, endolysosomal markers
were associated with the C. burnetii PV regardless of the presence or absence of
cholesterol, indicating that PV maturation was not cholesterol dependent. Here, we
made the surprising discovery that increasing cellular cholesterol is detrimental to
C. burnetii survival. C. burnetii is most sensitive to cholesterol during the early stages of
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infection, with increasing cholesterol levels leading to altered PV fusion, increased
acidity, and bacterial degradation. Cholesterol trafﬁcs to the PV and drugs that trap
cholesterol in the endolysosomal system are bactericidal, suggesting that PV choles-
terol inﬂuences PV biology and C. burnetii pathogenesis. These data strongly support
FIG 7 Cholesterol-altering FDA-approved drugs kill C. burnetii. C. burnetii-infected HeLa cells (3 days postinfection) were treated for 3 h with
the indicated drug (20 M) with or without the vATPase inhibitor baﬁlomycin A1 (100 nM). (A) Blocking acidiﬁcation with baﬁlomycin at least
partially rescues bacterial killing by amiodarone, clemastine, haloperidol, and spiperone. Values were normalized to the value with DMSO and
without baﬁlomycin, and the means plus SEM from three experiments are shown. ****, P 0.00001 compared to the value without baﬁlomycin,
as determined by two-way ANOVA with Sidek’s multiple-comparison test. (B) Filipin labeling of mCherry-C. burnetii-infected HeLa cells suggests
that amiodarone and clemastine alter cholesterol trafﬁcking. In amiodarone-treated cells, more ﬁlipin labeling in PVs is observed, while
clemastine-treated cells show an overall increase in ﬁlipin labeling around the PV. Coverslips were ﬁxed following drug treatment for 3 h, and
the cells were stained with ﬁlipin (cholesterol) and CD63. Filipin images were taken under identical capture settings and processed identically
in ImageJ. The ﬁlipin ﬂuorescence intensity is shown using a lookup table, with blue showing the lowest ﬂuorescence intensity and yellow
showing the highest ﬂuorescence intensity. The white arrows point to PVs, and representative PVs are shown in the insets. Bars  10 m.
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the conclusion that manipulating cholesterol in the bacterium-containing PV kills
C. burnetii.
C. burnetii growth is sensitive to drugs that target cholesterol biosynthesis and
uptake (19, 21). Further, Czyz et al. reported that treatment of THP-1 cells with
FDA-approved drugs that alter cellular cholesterol distribution similar to U18666A also
inhibit C. burnetii intracellular growth (19). In support of these data, they also showed
decreased C. burnetii growth in THP-1 macrophage-like cells deﬁcient in NPC-1, a
cholesterol transporter that facilitates cholesterol export from late endosomes and
lysosomes (19). We found that both plasma membrane cholesterol and the cholesterol-
binding exogenous protein LDL travel to the PV. We hypothesize that cholesterol
supplementation of cholesterol-free MEFs leads to increased cholesterol in the PV
membrane compared to cholesterol-free MEFs. Our model system further revealed that
C. burnetii PV size and bacterial growth are sensitive to cellular cholesterol, further
supporting the hypothesis that manipulating host cell cholesterol homeostasis ad-
versely affects C. burnetii infection. Importantly, our data show that rather than simply
blocking bacterial growth or PV formation, increasing PV cholesterol leads to C. burnetii
lysis. Remarkably, treatment for only 3 h with U18666A, which traps cholesterol in the
PV, killed 80% of the bacteria. These data, along with data from Czyz et al. (19), suggest
that C. burnetii is sensitive to altered cholesterol distribution within the cell, particularly
accumulation of cholesterol in the endosomal trafﬁcking pathway and the PV. With
other bacteria, including Chlamydia trachomatis, Staphylococcus aureus, and Mycobac-
terium spp., the presence of cholesterol is reported to be beneﬁcial to the bacterium,
with cholesterol depletion leading to reduced bacterial growth (11, 18, 42–46). The
unique sensitivity of C. burnetii to host cell cholesterol may reﬂect the distinctive
intracellular niche this bacterium occupies.
Cholesterol is a key regulator of endosomal trafﬁcking and fusion (47–49). We
previously found that the endosome marker CD63 was absent in the PV lumen in
cholesterol-free MEFs, suggesting that cholesterol is required for late endosomal
trafﬁcking to the PV (20). In this study, we discovered that lytic PVs containing degraded
C. burnetii, which are found only in cells with cholesterol, were no longer fusogenic with
the endosomal pathway. Most likely, bacterial degradation leads to a loss of the T4BSS
effector proteins required to maintain PV fusogenicity. The C. burnetii T4BSS is not
required for short-term intracellular survival, with a T4BSS mutant persisting for several
days in a viable form (25). Thus, it is unlikely that a cholesterol-dependent loss in PV
fusogenicity would lead to bacterial degradation. However, cholesterol is speciﬁcally
toxic to C. burnetii during the initial stages of PV biogenesis and expansion, and it is
possible that cholesterol plays a role in activating T4BSS secretion early during PV
development. Most likely, both the timing and amount of PV cholesterol are tightly
regulated by the bacteria to regulate PV-endosome fusion.
In addition to altered fusogenicity, the PVs from MEFs with cholesterol are signiﬁ-
cantly more acidic than PVs from cholesterol-free cells. Further, U18666A treatment also
increased PV acidity in a vATPase-dependent manner. Importantly, blocking acidiﬁca-
tion by vATPase also rescued bacterial viability, demonstrating that increasing the PV
acidity kills C. burnetii. This is a surprising ﬁnding, given that C. burnetii metabolism is
activated by acid (35, 39, 40) and the PV pH has previously been reported to be
approximately 4.8 (37, 38). Our studies found the PVs in cholesterol-free MEFs and HeLa
cells to be slightly more alkaline at pH 5.2. The differences in measured pH between
studies might be a result of different pH-sensitive reagents. We utilized the ﬂuorescein
derivative Oregon Green 488, given the improved pH sensitivity of Oregon Green 488
in acidic environments (41). A recent study on the role of lysosome-associated mem-
brane glycoprotein (LAMP) proteins in PV maturation found the pH of the PV to be
between 4.0 and 4.5 using LysoSensor Yellow/Blue DND-160 (50). In our hands, this
reagent stained the bacteria and was not free in the PV lumen, prompting us to utilize
the dual dextran labeling approach (41). Regardless, it is clear that the PV is more acidic
in MEFs with cholesterol and HeLa cells treated with U18666A, and this increased
acidity kills C. burnetii. However, the mechanism behind C. burnetii degradation is not
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known. Host cathepsin D and lysosomal acid phosphatases accumulate in the PV (35),
and the PV is proteolytically active, presumably due to the presence of host proteases
(51). It is possible that increased acidity further activates lysosomal degradative en-
zymes beyond the threshold the bacteria can survive. Detailed characterization of the
PV proteolytic activity is needed to fully understand how C. burnetii survives in this
environment.
Previously, a drug screen revealed that C. burnetii growth is sensitive to 57 FDA-
approved drugs that perturb host cell cholesterol homeostasis (19, 21). We used several
drugs from this screen to further validate our hypothesis that C. burnetii lysis was due
to cholesterol-induced changes in the PV pH. Treatment with six of the eight selected
drugs resulted in signiﬁcant C. burnetii lysis which could be at least partially rescued by
blocking acidiﬁcation through vATPase. Importantly, these drugs were shown to have
little to no effect on C. burnetii growth in axenic media or on host cell viability (19).
While the mode of action differs between these drugs, we conﬁrmed the results of
previous studies that they altered cholesterol distribution within the cell (19). Treat-
ment with several of these drugs appeared to increase cholesterol within the PV.
Together, these ﬁndings reveal a potential vulnerability in the C. burnetii lifestyle which
could be targeted with currently available drugs.
The cholesterol-mediated negative effect on intracellular C. burnetii raises intriguing
questions as to how C. burnetii successfully colonizes cholesterol-containing cells
during natural infection, given that cholesterol is an essential lipid for host cells outside
the laboratory setting. Accumulating evidence suggests that C. burnetii possesses
multiple mechanisms to manipulate host cholesterol metabolism. For example, Howe
and Heinzen reported differential expression of cholesterol biosynthesis-related genes
in C. burnetii-infected Vero cells (21). Expression proﬁling of C. burnetii-infected THP-1
cells suggests that C. burnetii actively upregulates expression of apoE and plin2, which
are involved in cholesterol efﬂux and storage, respectively (26, 27). Beyond gene
expression, cholesterol storage organelles called lipid droplets have been observed in
and around the PVs of infected primary human alveolar macrophages (52). It is possible
that C. burnetii targets the carefully regulated host cholesterol homeostasis, upregu-
lating storage and efﬂux while also decreasing biosynthesis. In addition, we recently
showed that C. burnetii recruits the host cell sterol-binding protein ORP1L to the PV,
where it participates in membrane contact sites between the PV and endoplasmic
reticulum (53). Finally, C. burnetii expresses two eukaryote-like sterol reductase enzymes
that could modify cholesterol (54). This intriguing possibility might explain the intense
ﬁlipin labeling of the PV, with a bacterium-derived -hydroxysterol other than choles-
terol dominating the PV membrane.
In summary, our data suggest that the presence of cholesterol in the PV during the
initial phases of PV formation negatively affects PV formation and C. burnetii survival.
While not absolutely required for C. burnetii growth, some cholesterol is needed for
optimal PV development through fusion with late endosomes (20). However, too much
PV membrane cholesterol leads to increased PV acidiﬁcation, decreased fusion with
endosomes, and eventual bacterial degradation. We propose that the amount of
cholesterol in the PV membrane regulates key aspects of PV function, and C. burnetii
must maintain a delicate balance of PV membrane cholesterol. This would explain the
unique sensitivity of C. burnetii to drugs that target different aspects of host cholesterol
metabolism: any slight shift in host cholesterol homeostasis would impact PV mem-
brane cholesterol levels. Identifying both the bacterial and host pathways involved in
this delicate balance may yield novel targets to treat or prevent C. burnetii pathogen-
esis.
MATERIALS AND METHODS
Bacteria and mammalian cells. Coxiella burnetii Nine Mile Phase II (NMII) (clone 4, RSA439) and
mCherry-expressing C. burnetii NMII (55) were puriﬁed from Vero cells (African green monkey kidney
epithelial cells [ATCC CCL-81; American Type Culture Collection, Manassas, VA]) and stored as previously
described (56). Vero cells were maintained in RPMI 1640 medium (Corning, New York, NY) containing
10% fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA) at 37°C and 5% CO2. DHCR24/ mouse
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embryonic ﬁbroblasts (MEFs) were cultured in ﬁbroblast media supplemented with serum-free growth kit
(ATCC) and cholesterol (Synthechol; Sigma-Aldrich, St. Louis, MO) as previously described (20). The
multiplicity of infection (MOI) was optimized for each bacterial stock, cell type, and infection condition
for a ﬁnal infection of ca. one internalized bacterium/cell at 37°C and 5% CO2.
PV measurements. A total of 5  104 MEFs were plated onto ibidi-treated channel slide VI0.4 (3 
103 cells per channel; ibidi USA Inc., Verona, WI) and allowed to adhere overnight. After the MEFs were
infected with C. burnetii for 1 h, they were washed with phosphate-buffered saline (PBS) to remove
extracellular bacteria and incubated in media containing the indicated cholesterol concentrations. At
different time points postinfection, cells were ﬁxed with 2.5% paraformaldehyde (PFA) on ice for 15 min
and then permeabilized/blocked for 15 min with 0.1% saponin and 1% bovine serum albumin (BSA) in
PBS. The cells were incubated with rat anti-LAMP1 (catalog no. 553792; BD Biosciences, San Jose, CA) and
rabbit anti-C. burnetii primary antibodies in saponin-BSA-PBS for 1 h, followed by Alexa Fluor secondary
antibodies (Invitrogen) for 1 h. Following washing with PBS, ProLong Gold with 4=,6=-diamidino-2-
phenylindole (DAPI) (Invitrogen) was added, and the cells on the slides were visualized on a Leica
inverted DMI6000B microscope (63 oil immersion objective). Images were captured and processed
identically, and a cross-sectional area through the middle of the PV was measured using ImageJ software.
Approximately 20 PVs were measured per condition for each of three independent experiments.
C. burnetii growth in MEFs.MEFs were plated at 1 105 cells/well in a six-well plate under different
cholesterol conditions and allowed to adhere overnight. After the MEFs were infected with C. burnetii for
1 h in 500 l medium, the wells were washed with PBS to remove extracellular bacteria and then gently
scraped into 3 ml of medium. For the day 0 sample, 1 ml of the cell suspension was centrifuged at
20,000  g for 10 min, and the pellet was frozen at 20°C. The remaining cells were left in the six-well
plate in medium supplemented with cholesterol. The medium was changed daily to ensure constant
cholesterol concentrations. At 6 days postinfection, the cells were harvested by scraping the cells into the
growth medium and centrifuging at 20,000  g for 10 min. Bacterial DNA was extracted from the pellets
using the UltraClean microbial DNA isolation kit (Mo Bio Laboratories, Carlsbad, CA) according to the
manufacturer’s instructions. Quantitative PCR for genome equivalents was performed using a primer set
speciﬁc for dotA (30) and Luminaris Color HiGreen quantitative PCR (qPCR) master mix (Thermo Scientiﬁc)
with an Applied Biosystems 7500 real-time PCR cycler. Each experiment was done in duplicate.
Quantitation of lytic PVs containing lysed C. burnetii. DHCR24/ MEFs were plated under
different cholesterol conditions at 5  104 cells per well of a six-well plate and infected with mCherry-
expressing C. burnetii (mCherry-C. burnetii) for 1 h as described above. Approximately 24 h later, the cells
were scraped into fresh medium, resuspended to 1  105 cells/ml, and plated onto ibidi-treated channel
slide VI0.4 (3  103 cells per channel). The medium was changed daily, and cells were examined live
every 24 h on a Leica inverted DMI6000B microscope with a 63 oil immersion objective. PVs with visible
mCherry ﬂuorescence in the PV lumen were scored as “lytic PVs” with 50 PVs scored for each condition
for three individual experiments.
HeLa cells (5  104) were infected with mCherry-C. burnetii in 6-well plates for 1 h. At 2 days
postinfection, the cells were trypsinized and resuspended to 1  105 cells/ml, and plated onto
ibidi-treated channel slide VI0.4 (3  103 cells per channel; Ibidi). At 3 days postinfection, dimethyl
sulfoxide (DMSO) control, U18666A (1 or 5 M), or the indicated FDA-approved drugs (see Table S1 in
the supplemental material; obtained from Sigma and used at a ﬁnal concentration of 20 M) with or
without vATPase inhibitor baﬁlomycin A1 (100 nM) were added to the cells and incubated for the time
indicated prior to counting lytic PVs as described above. At least 50 PVs were scored for each condition
for three individual experiments.
C. burnetii viability by ﬂuorescent infectious focus-forming unit (FFU) assay. To test viability of
C. burnetii in MEFs under different cholesterol conditions, 1 104 cells/well were infected with C. burnetii
for 1 h in a 48-well plate, washed extensively with PBS, and incubated with media containing different
cholesterol concentrations. At the indicated time points, cells were incubated for 5 min with sterile water,
pipetted up and down to lyse cells, and diluted 1:5 in RPMI 1640 with 2% FBS (2% FBS-RPMI). Serial
dilutions were added to conﬂuent monolayers of Vero cells in a 24-well plate and incubated for 5 days.
Plates were ﬁxed with methanol and stained with rabbit anti-C. burnetii antibody and DAPI to conﬁrm
monolayer integrity. Four ﬁelds per well were captured on an Evos automated microscope (Thermo
Fisher) with a 4X objective, and ﬂuorescent focus units were quantitated using ImageJ. Each experiment
was done in duplicate.
To determine bacterial viability in drug-treated cells, HeLa cells were plated at 5  104 cells/well in
a six-well plate and infected with mCherry-C. burnetii. At 2 days postinfection, the cells were trypsinized
and replated in 24-well plates at 5  104 cells/well. Approximately 16 h later, the cells were treated with
DMSO or drug with or without the vATPase inhibitor baﬁlomycin A1 (100 nM) for the time indicated, at
which point the medium was aspirated from the 24-well plate and the cells were lysed by incubation in
sterile water for 5 min. After the cells were pipetted up and down, the released bacteria were diluted 1:5
in 2% FBS-RPMI and plated in 10-fold serial dilutions onto conﬂuent Vero cell monolayers in a 96-well
ibidi-treated plate (ibidi). The plate was ﬁxed with 2.5% PFA 5 days later and stained with DAPI, and the
number of ﬂuorescent foci was determined as described above. Each experiment was done in duplicate.
Microscopy for cholesterol trafﬁcking. To monitor trafﬁcking of plasma membrane cholesterol,
ﬂuorescent cholesterol (TopFluor cholesterol; Avanti Polar Lipids) was resuspended at 20 mg/ml in
ethanol. Twenty microliters of this solution was added to 1 ml of 10% methyl-beta-cyclodextrin (Sigma)
in serum-free RPMI 1640 medium. The solution was sonicated in a water bath sonicator (Avanti) for 30 s,
and insoluble material was pelleted by spinning for 2 min at 20,000  g. MEFs with cholesterol were
infected with mCherry-C. burnetii and plated onto an ibidi slide as described above. At 3 days
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postinfection, ﬂuorescent cholesterol (ﬁnal concentration of 30 g/ml) was added to the cells for 24 h.
Live-cell images were taken with a modiﬁed PerkinElmer UltraView spinning disk confocal connected to
a Nikon Eclipse Ti-E inverted microscope with a 63 oil immersion objective.
For trafﬁcking of BODIPY-LDL, MEFs were infected and plated onto an ibidi slide as described above.
The cells were incubated for 5 min on ice with 25 g/ml BODIPY-LDL (Invitrogen), washed twice with
medium, and visualized after 4 h of incubation at 37°C.
To visualize endogenous free sterols after drug treatment, infected cells were plated onto ibidi
slides and treated as described above. The cells were ﬁxed with 2.5% PFA on ice for 15 min and
incubated with 1:100 ﬁlipin (Cayman Chemicals, Ann Arbor, MI) in PBS with 1% BSA for 1 h. After the cells
were washed with PBS three times, they were incubated with rat anti-LAMP1 for MEFs (catalog no.
553792; BD Biosciences, San Jose, CA) or mouse anti-CD63 for HeLa cells for 1 h, followed by three
washes in PBS and a 1 h incubation with Alexa Fluor 488 anti-mouse secondary antibody. After the cells
were washed three times with PBS, ProLong Gold was added to the wells, and samples were visualized
on a Leica inverted DMI6000B microscope (63 oil immersion objective). Images were captured under
identical capture settings and processed identically using ImageJ.
C. burnetii growth in cell-free media. To complex cholesterol to BSA, 500 g of cholesterol
(10 mg/ml chloroform stock; Avanti) was dried down in a glass tube under a nitrogen stream. The lipid
ﬁlm was resuspended into 2.5 ml of 5% fatty acid-free BSA using a water bath sonicator (Avanti). The
resulting 200 g/ml stock was sterile ﬁltered and added to a ﬁnal concentration of 5 g/ml in ACCM-2
(40). C. burnetii bacteria were diluted to approximately 1  105 genomes/ml in ACCM-2 with BSA or
BSA-cholesterol, and 7 ml was transferred to a T25 ﬂask and incubated as previously described (40). Every
24 h, 50 l was removed and added to a tube with 150 l PBS and a half volume of 0.1-mm zirconia-silica
beads (BioSpec Products, Bartlesville, OK). Bacteria were lysed by bead beating in a FastPrep FP120
(Thermo Scientiﬁc) and analyzed by qPCR as previously described (20). Each experiment was done in
duplicate.
To test bacterial sensitivity to U18666A, ACCM-2 was inoculated at approximately 1 105 bacteria/ml
with mCherry-C. burnetii and grown for 5 days as previously described (40). Bacteria (500 l) were treated
for 6 h with DMSO or U18666A in 24-well plates under normal C. burnetii culture conditions. The bacteria
were diluted 1:10 in 2% FBS-RPMI prior to the FFU assay in 96-well ibidi-treated plates as described
above.
Dextran trafﬁcking. Cells were infected with mCherry-C. burnetii in six-well plates and replated onto
ibidi slides at 2 days postinfection as described above. PVs were selected and marked in Elements
software on the spinning disk confocal microscope in a live-cell environmental chamber. Individual ibidi
channels were pulsed with 1 mg/ml Alexa Fluor 488-dextran (molecular weight [MW] of 10,000) for
10 min in medium, followed by four washes with medium to remove uninternalized dextran and ﬁnally
replaced with either basal medium or basal medium with cholesterol (5 g/ml). The PVs were then
focused, and confocal images through the entire PV were obtained every 6.33 min for 38 min. The
ﬂuorescence intensity of dextran inside the PV was calculated using the average intensity multiplied by
the PV volume using ImageJ.
PV pH measurements. The pH measurement was performed as previously described with slight
modiﬁcations (57). Brieﬂy, MEFs were infected with mCherry-C. burnetii in six-well plates, incubated with
and without cholesterol, and replated onto ibidi slides at 2 days postinfection as described above. For
measurement of PV pH in U18666A-treated cells, HeLa cells were infected with mCherry-C. burnetii in
six-well plates and replated onto ibidi plates at 2 days postinfection. Under both conditions, at 3 days
postinfection, cells were incubated with pH-sensitive Oregon Green 488 dextran (MW, 10,000; Invitrogen)
and pH-stable Alexa Fluor 647 dextran (MW, 10,000; Invitrogen) for 4 h at a concentration of 0.5 mg/ml.
MEFs were imaged directly with a 63 oil immersion objective under identical capture settings.
To measure the time-dependent change in PV pH, individual PVs were selected and imaged, and then
treated with 5 M U18666A or DMSO as a vehicle control. Starting from 15 min after the treatment, cells
were then imaged every 15 min for the next 2 h. The PV ﬂuorescence intensity was measured using
ImageJ, and the Oregon Green 488/Alexa Fluor 647 ratio was calculated. To generate a standard curve
for MEFs and HeLa cells, the respective infected cells were incubated with the ionophores nigericin
(10 M) and monensin (10 M) for 5 min at room temperature, followed by buffers with different pHs
(pH 4.0 to 7.0) before imaging. At least 20 PVs were imaged at each pH for every experiment, and the
ratio of ﬂuorescence intensity at 488/647 nm were plotted against the pH of the respective buffer to
obtain a sigmoidal standard curve.
Data analyses. Image processing and analysis were done with ImageJ software (W. S. Rasband,
National Institutes of Health, Bethesda, MD) (58). Statistical analyses were performed using unpaired
two-tailed t test, ordinary one-way or two-way analysis of variance (ANOVA) with Tukey’s or Dunnett’s
multiple-comparison test in Prism (GraphPad Software, Inc., La Jolla, CA).
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